(Q48573282)

12 February 2018

title

Bortezomib regulates the chemotactic characteristics of T cells through downregulation of CXCR3/CXCL9 expression and induction of apoptosis (English)

1 reference

12 February 2018

0 references

1 reference

Wei Liu

1

1 reference

12 February 2018

Han-Yun Ren

2

1 reference

12 February 2018

Yu-Jun Dong

3

1 reference

12 February 2018

Li-Hong Wang

4

1 reference

12 February 2018

Yue Yin

5

1 reference

12 February 2018

Yuan Li

6

1 reference

12 February 2018

Zhi-Xiang Qiu

7

1 reference

12 February 2018

Xi-Nan Cen

8

1 reference

12 February 2018

Yong-Jin Shi

9

1 reference

12 February 2018

publication date

23 November 2012

1 reference

12 February 2018

International Journal of Hematology

published in

1 reference

12 February 2018

volume

96

1 reference

12 February 2018

issue

6

1 reference

12 February 2018

page(s)

764-772

1 reference

12 February 2018

Pathophysiology of graft-versus-host disease

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

A revision of Billingham's tenets: the central role of lymphocyte migration in acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

Leukocyte migration and graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

CCR7 and its ligands: balancing immunity and tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

Increase of CCR7- CD45RA+ CD8 T cells (T(EMRA)) in chronic graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

Impaired effector memory T-cell regulation facilitates graft versus host disease in CCR7-deficient bone marrow transplant chimeras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

Lymphocyte traffic control by chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

Increased gene expression of chemokine receptors is correlated with acute graft-versus-host disease after allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

Ubiquitin makes its mark on immune regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

Ubiquitin and ubiquitin-like proteins in cancer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

The development of proteasome inhibitors as anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

The proteasome: a suitable antineoplastic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

NF-kappa B as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

Proteasome inhibition suppresses essential immune functions of human CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

The Erk2 MAPK regulates CD8 T cell proliferation and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

BCL-2 family regulation by the 20S proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

Transcription factors of the NFAT family: regulation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

The interleukin 2 receptor alpha chain/CD25 promoter is a target for nuclear factor of activated T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1195-6

Blockade of CXCR3 Receptor:Ligand Interactions Reduces Leukocyte Recruitment to the Lung and the Severity of Experimental Idiopathic Pneumonia Syndrome

21 January 2018

1 reference

12 December 2020

Early changes in gene expression profiles of hepatic GVHD uncovered by oligonucleotide microarrays

1 reference

12 December 2020

[Increment of chemokine CXCL9/Mig in plasma correlated with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation]

1 reference

12 December 2020

Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma

1 reference

12 December 2020

Role of CXCR3-induced donor T-cell migration in acute GVHD

1 reference

12 December 2020

A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody

1 reference

12 December 2020

Chemokine and chemokine receptor expression analysis in target organs of acute graft-versus-host disease

1 reference

12 December 2020

Graft-versus-host disease

1 reference

12 December 2020

Chemokines and chemokine receptors in hematopoiesis and immunology

1 reference

12 December 2020

10.1007/S12185-012-1195-6

Identifiers

DOI

1 reference

12 February 2018

1 reference

12 February 2018